Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
THLD's Cash to Debt is ranked higher than
94% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. THLD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
THLD' s 10-Year Cash to Debt Range
Min: 17.14  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset -0.23
THLD's Equity to Asset is ranked lower than
95% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. THLD: -0.23 )
Ranked among companies with meaningful Equity to Asset only.
THLD' s 10-Year Equity to Asset Range
Min: -0.86  Med: 0.48 Max: 0.88
Current: -0.23
-0.86
0.88
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
88% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
THLD' s 10-Year Interest Coverage Range
Min: 725.64  Med: 10000.00 Max: 9999.99
Current: No Debt
725.64
9999.99
F-Score: 3
Z-Score: -4.54
M-Score: -3.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -219.13
THLD's Operating margin (%) is ranked lower than
63% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. THLD: -219.13 )
Ranked among companies with meaningful Operating margin (%) only.
THLD' s 10-Year Operating margin (%) Range
Min: -48445.16  Med: -1776.88 Max: -208.28
Current: -219.13
-48445.16
-208.28
Net-margin (%) -174.09
THLD's Net-margin (%) is ranked lower than
61% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. THLD: -174.09 )
Ranked among companies with meaningful Net-margin (%) only.
THLD' s 10-Year Net-margin (%) Range
Min: -41375.81  Med: -1702.83 Max: -146.61
Current: -174.09
-41375.81
-146.61
ROA (%) -31.11
THLD's ROA (%) is ranked lower than
54% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. THLD: -31.11 )
Ranked among companies with meaningful ROA (%) only.
THLD' s 10-Year ROA (%) Range
Min: -132.78  Med: -65.37 Max: -25.02
Current: -31.11
-132.78
-25.02
ROC (Joel Greenblatt) (%) -5342.83
THLD's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. THLD: -5342.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8350.75  Med: -2871.74 Max: 2566.56
Current: -5342.83
-8350.75
2566.56
EBITDA Growth (3Y)(%) -9.80
THLD's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. THLD: -9.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
THLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -73.4  Med: -42.60 Max: -9.8
Current: -9.8
-73.4
-9.8
EPS Growth (3Y)(%) -13.70
THLD's EPS Growth (3Y)(%) is ranked lower than
58% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. THLD: -13.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
THLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.5  Med: -45.25 Max: 2.7
Current: -13.7
-85.5
2.7
» THLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

THLD Guru Trades in Q2 2014

Jim Simons 402,886 sh (+110.64%)
First Eagle Investment 800,000 sh (+14.29%)
» More
Q3 2014

THLD Guru Trades in Q3 2014

First Eagle Investment 1,091,700 sh (+36.46%)
Jim Simons 40,700 sh (-89.90%)
» More
Q4 2014

THLD Guru Trades in Q4 2014

Jim Simons 177,615 sh (+336.40%)
First Eagle Investment 1,377,448 sh (+26.17%)
» More
Q1 2015

THLD Guru Trades in Q1 2015

Jim Simons 346,308 sh (+94.98%)
First Eagle Investment 1,405,768 sh (+2.06%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 17.25
THLD's P/S is ranked lower than
60% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. THLD: 17.25 )
Ranked among companies with meaningful P/S only.
THLD' s 10-Year P/S Range
Min: 1.77  Med: 39.00 Max: 1242
Current: 17.25
1.77
1242
Current Ratio 2.83
THLD's Current Ratio is ranked lower than
64% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. THLD: 2.83 )
Ranked among companies with meaningful Current Ratio only.
THLD' s 10-Year Current Ratio Range
Min: 1.48  Med: 5.16 Max: 13.48
Current: 2.83
1.48
13.48
Quick Ratio 2.83
THLD's Quick Ratio is ranked lower than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. THLD: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
THLD' s 10-Year Quick Ratio Range
Min: 1.48  Med: 5.16 Max: 13.48
Current: 2.83
1.48
13.48
Days Sales Outstanding 49.41
THLD's Days Sales Outstanding is ranked higher than
63% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. THLD: 49.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
THLD' s 10-Year Days Sales Outstanding Range
Min: 179.7  Med: 528.56 Max: 972.69
Current: 49.41
179.7
972.69

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.44
THLD's Price/Median PS Value is ranked higher than
88% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. THLD: 0.44 )
Ranked among companies with meaningful Price/Median PS Value only.
THLD' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.70 Max: 29.89
Current: 0.44
0.08
29.89
Earnings Yield (Greenblatt) (%) -14.86
THLD's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. THLD: -14.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
THLD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.86  Med: 297.90 Max: 14657.5
Current: -14.86
-14.86
14657.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NZW1.Germany,
Threshold Pharmaceuticals Inc is a Delaware corporation incorporated on October 17, 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for THLD

Headlines

Articles On GuruFocus.com
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare Con Jul 01 2015 
Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus De Dec 06 2014 
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in Dece Nov 25 2014 
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevaciz Nov 17 2014 
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previo Nov 11 2014 
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conferenc Nov 10 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented Nov 06 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at Nov 03 2014 
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in th Nov 03 2014 

More From Other Websites
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year Jul 02 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare... Jul 01 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 10 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 01 2015
Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCO May 31 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies 2015 Healthcare... May 27 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies 2015 Healthcare... May 27 2015
Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be... May 13 2015
Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be... May 13 2015
5 New Biotech Developments Worth Watching May 13 2015
Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation May 12 2015
Merck KGaA, Threshold win fast track for pancreatic cancer drug May 12 2015
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track... May 12 2015
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track... May 12 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare... May 11 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare... May 11 2015
Are These in Your Portfolio? 4 Trending Companies (GALE, AEZS, PPCH, THLD) May 06 2015
10-Q for Threshold Pharmaceuticals, Inc. May 03 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK